Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994
An Algorithm for the Management of Parkinson's Disease
Neurol 44:S1-S52, Koller,W.C.,et al, 1994
Increased Risk of Parkinson's Disease in Parents and Siblings of Patients
Ann Neurol 36:659-661, Payami,H.,et al, 1994
Botulinum Toxin-A Improves the Rigidity of Progressive Supranuclear Palsy
Ann Neurol 35:237-239, Polo,K.B.&Jabbari,B., 1994
Physical Therapy and Parkinson's Disease:A Controlled Clinical Trial
Neurol 44:376-378, Comella,C.L.,et al, 1994
Reverse Shapiro's Syndrome:Hirayama
K. , et al, Arch Neurol 51:494-49694., , 1994
Hemiballism:Report of 25 Cases
JNNP 57:945-949, Vidakovic,A.,et al, 1994
Progressive Supranuclear Palsy:Neuropathologic and Clinical Heterogeneity
Neurol 44:1015-1024, Gearing,M.,et al, 1994
The Syndrome of'Pure Akinesia'and Its Relationship to Progressive Supranuclear Palsy
Neurol 44:1025-1029, Riley,D.E.,et al, 1994
The Relationship of Essential Tremor to Other Movement Disorders:Report on 678 Patients
Ann Neurol 35, 717-7231994., Koller,W.C.,et al, 1994
Clinical Assessment of Extrapyramidal Signs in Nursing Home Patients Given Antipsychotic Medication
Arch Int Med 154:1113-1117, Avorn,J.,et al, 1994
Levodopa Failure in Chronic Manganism
Neurol 44:1600-1602, 15831994., Lu,C-S.,et al, 1994
Radiologic-Clinical Correlation:Hemiballismus
AJNR 15:1377-1382, Provenzale,J.M.&Schwarzschild,M.A., 1994
Reversal of Amphotericin-B-Related Encephalopathy
Neurol 44:1183-1184, Balmaceda,C.M.,et al, 1994
Oxidative Damage in Neurodegenerative Disease
Lancet 344:796-798, Jenner,P., 1994
Dopa-Responsive Dystonia:Pathological and Biochemical Observations in a Case
Ann Neurol 35:396-402, 3811994., Rajput,A.H.,et al, 1994
Eye Movements in Parkinsonian Syndromes:Vidailhet
M. , et al, Neurol 35:420-42694., , 1994
A Multicenter Double-Blind Placebo-Controlled Trial of Pergolide as an Adjunct to Sinemet in Parkinson's Disease
Movement Disorders, 9:40-471994., Olanow,C.W.,et al, 1994
Sleep Disruption in Parkinson's Disease:Assessment by Continuous Activity Monitoring
Arch Neurol 51:922-928, vanHilten,B.,et al, 1994
Diff Diag of parkinson's Disease, Multiple Sys Atrophy, & Steele-Richardson-Olszewski Syndrome:Striatal F-Dopa PET Data
JNNP 57:278-284, Burn,D.J.,et al, 1994
Four-Year Follow-up of Adrenal-to-Brain Transplants in Parkinson's Disease
Arch Neurol 51:559-563, Diamond,S.G.,et al, 1994
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Therapy of Patients with Parkinson's Disease
Arch Neurol 51:754-756, Paulson,G.W., 1994
Parkinsonism Induced by Solvent Abuse
Ann NEurol 35:616-618, Uitti,R.J.,et al, 1994
Parkinsonism Caused by Petroleum Waste Ingestion
Neurol 44:1051-1054, Tetrud,J.W.,et al, 1994
Movement Disorders Following Lesions of the Thalamus or Subthalamic Region
Mov Disord 9:493-507, Lee,M.S. &Marsden, C.D., 1994
Gene Therapy for Neurologic Disease
Arch Neurol 50:1252-1268, Suhr,S.T.&Gage,F.H., 1993
Prolactin-Secreting Macroadenomas in Adolescents, Response to Bromocriptine Therapy
Am J Dis Child 147:1057-1061, Tyson,D.,et al, 1993
Autosomal Dominant Parkinsoniam with Benign Course and Typical Lewy-Body Pathology
Neurol 43:2222-2227, Golbe,L.I.,et al, 1993
Risk Factors for Nursing Home Placement in Advanced Parkinson's Disease
Neurol 43:2227-2229, Goetz,C.G.&Stebbins,G.T., 1993
Fatigue in Parkinson's Disease
Neurol 43:2016-2018, Friedman,J.&Friedman,H., 1993
Cabergoline in Parkinson's Disease:Long-Term Follow-up
Neurol 43:2587-2590, Lera,G.,et al, 1993
Multictr Study of Cabergoline, A Long-Acting Dopamine Receptor Agonist, in PD Fluct Resp to Levodopa/Carbidopa
Neurol 43:1981-1984, Lieberman,A.,et al, 1993
Prognostic Significance of the Onset Mode in Parkinsonism
Neurol 43:829-830, Rajput,A.H.,et al, 1993
PET Imaging of the Dopamine Transporter with 11C-WIN 35, 428 Reveals Marked Declines in Mild Parkinson's Disease
Ann Neurol 34:423-431, Frost,J.J.,et al, 1993
Levodopa Improves Spatial Contrast Sensitivity in Parkinson's Disease
Arch Neurol 50:721-724, Hutton,J.T.,et al, 1993
T2 Relaxation Time in Patients with Parkinson's Disease
Neurol 43:697-700, Antonini,A.,et al, 1993
The Spectrum of Levodopa-Related Fluctuations in Parkinson's Disease
Neurol 43:1459-1464, Riley,D.E.&Lang,A.E., 1993
Blood Levodopa Levels and Unified Parkinson's Disease Rating Scale Function:With and Without Exercise
Neurol 43:1040-1042, Goetz,C.G.,et al, 1993
Contrast Agent Overdose Causing Brain Retention of Contrast, Seizures, and Parkinsonism
Neurol 43:836-838, May,E.F.,et al, 1993
Treatment of Parkinson's Disease
NEJM 329:1021-1027, Calne,D.B., 1993
Clinicopath Conf
progressive Supranuclear Palsy, Case 46-1993, NEJM 329:1560-1567993., , 1993
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group, NEJM 328:176-1831993., , 1993
Neurosurgical Horizons in Parkinson's Disease
Neurol 43:1-7, Goetz,C.G.,et al, 1993
A Clinicopathologic Study of 100 Cases of Parkinson's Disease
Arch Neurol 50:140-148, Hughes,A.J.,et al, 1993
Increase of Parkinson Disability after Fluoxetine Medication
Neurol 43:211-213, Steur,E.N.H.J., 1993
Dopaminergic Treatment of Restless Legs and Rebound Phenomenon
Neurol 43:455, Guilleminault,C.,et al, 1993
Functional Integration of Cortical Grafts Placed in Brain Infarcts of Rats
Ann Neurol 34:362-368, Grabowski,M.,et al, 1993
Transplants for Stroke Patients
Ann Neurol 34:322-323, Sharp,F.R., 1993
Subcortical Dementia
BMJ 307:1-2, Dunne,F.J., 1993